Radioactive microparticles aim to boost chemo against tough pancreatic cancer
NCT ID NCT05466799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding tiny radioactive beads (OncoSil™) directly into the tumor can improve outcomes for people with locally advanced pancreatic cancer that cannot be removed by surgery. About 88 participants will receive either standard FOLFIRINOX chemotherapy alone or chemotherapy plus the implanted radiation. The study tracks safety and how well the tumor is controlled at 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OncoSil™ (phosphorus-32 microparticles) plus FOLFIRINOX chemotherapy
What this could lead to
If successful, this could offer a new treatment option that improves local tumor control and survival for people with inoperable pancreatic cancer.
What could go wrong
This is a phase 2 trial with only 88 participants, so results are preliminary. Adding a device to chemotherapy may increase side effects, and the treatment may not improve outcomes enough to reach standard practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Maria Middelares
Ghent, Belgium
-
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Freeman Hospital
Newcastle upon Tyne, United Kingdom
-
Guy's Hospital
London, United Kingdom
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario 12 de Octobre
Madrid, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hospital Universitario de Fuenlabrada
Madrid, Spain
-
Royal Adelaide Hospital
Adelaide, South Australia, Australia
-
San Camillo Forlanini
Rome, Italy
-
The Christie Hospital/Manchester Royal Infirmary
Manchester, United Kingdom
-
University Hospital Southampton
Southampton, United Kingdom